Immunol Res News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Immunol res. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Immunol Res Today - Breaking & Trending Today

Molecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533's Proposed Mechanism of Action

Preclinical data of tetra-specific T cell engager MP0533 demonstrate preferential T cell mediated killing of AML cells, while sparing healthy cellsResults highlight MP0533-mediated T-cell activation. ....

United States , Seth Lewis , Laura Jeanbart , University Of Bern , Cancer Immunology Research , American Association For Cancer Research , Head Of Portfolio Management Communications , Exchange Commission , American Society Of Hematology , American Association , Cancer Research The , American Society , Annual Meeting , Selectivet Cell , Mediated Killing , Immunol Res , Designed Ankyrin Repeat Protein , Portfolio Management , Private Securities Litigation Reform Act , Molecular Partner , Risk Factors , Molecular Partner Annual Report , Molecular Partners ,

Lung cancer

Lung cancer
thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.

South Korea , Switzerland General , Kyongsang Namdo , United States , United Kingdom , Japan General , Comunidad Autonoma De Cataluna , Diaz Jr , Chen Chao , William Jr , Bunn Jr , Bernabe Caro , Le Pechoux , J Thorac Cardiovasc , Semin Thorac Cardiovasc , American Society Of Clinical Oncology , Health Information National Trends , College Of American Pathologists , Treatment Of Cancer Early Clinical Studies Group , Navelbine International Trialist Association , Drug Development Office , Big Ten Cancer Research Consortium , Oncology Alliance , Oncology Congress , European Society Of Thoracic Surgeons , International Agency For Research On Cancer ,

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.

United States , South Korea , Kangwon Do , Berge Henegouwen , Arbeitsgemeinschaft Internistische Onkologie , Van Cutsem , Japanese Gastric Cancer Association , Cancer Genome Atlas Research Network , European Society For Medical Oncology , Chinese Society Of Clinical Oncology , National Comprehensive Cancer Network , Rev Dis Primers , Practice Guidelines , Chinese Society , Clinical Oncology , Clin Oncol , Biophys Res Commun , Immunol Res , Thorac Dis , Cell Int , Medical Oncology , Arbeitsgemeinschaft Internistische , Englj Med , ஒன்றுபட்டது மாநிலங்களில் , தெற்கு கொரியா , புற்றுநோய் மரபணு அட்லஸ் ஆராய்ச்சி வலைப்பின்னல் ,

Will Immunotherapy Work as Salvage Therapy for Patients with Testicular Germ Cell Tumors?

Published 01 March 2021
It’s now been 3.5 years since I last wrote anything about testicular germ cell tumors and ongoing clinical trials.
1 Although we still cure most men afflicted with this disease, we have not made any major new therapeutic advancements since I wrote that last article. Approximately, 15-20% of patients with metastatic germ cell tumors will relapse following initial chemotherapy. Even in this situation, approximately 50% can still be cured with salvage treatments, either with more conventional cisplatin-based chemotherapy or with high-dose chemotherapy and autologous stem cell rescue.
2-4 However, patients with cisplatin-refractory disease or progressive disease following high-dose salvage chemotherapy and autologous stem cell rescue, harbor an extremely dim prognosis. In these situations, palliative chemotherapy, with regimens containing oxaliplatin, is limited in efficacy, and targeted biologic therapies have also shown limited effic ....

Fred Hutchinson Cancer Research Center , United States , University Of Washington , Evan Yu , Clinical Research Division , Clinical Research Service , Seattle Cancer Care Alliance , Clinical Research , Hoosier Cancer Research Network Study , Fred Hutchinson Cancer Research Consortium , University Of Washington School Medicine , Division Of Oncology , Department Of Medicine , Washington School , Clinical Research Director , Genitourinary Oncology , Medical Director , Stem Cell Rescue , Metastatic Germ Cell , Englj Med , German Testicular Cancer Study , Clin Oncol , Surg Case , Immune Cell Infiltrate , Immune Checkpoint Molecules , Immune Landscape ,